FDA is asking for public comment on a risk assessment it conducted of drug residues in milk and milk products. The risk assessment was conducted as part of the agency's effort to improve its regulatory system for milk and milk products. The risk assessment considered a wide range of data and information and reviewed four overarching criteria that factored into the drug's ranking, including the likelihood that the drug will be administered to lactating dairy cows, the likelihood that drug residues would be present in bulk milk, the relative extent of human exposure to the drug residue, and the potential for health hazards from the drug residue. FDA is particularly interested in comments on its ranking model approach, including the specific criteria, scoring, and weighting scheme; the assumptions and scientific data used to inform how the animal drugs were scored in the model; the selection of animal drugs evaluated; and the clarity and transparency of the risk assessment. FDA is accepting comments beginning April 30, 2015.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.